Analysis
Zoetis (ZTS) has faced manageable headwinds from U.S. tariffs enacted in early 2025, primarily affecting its livestock and diagnostics segments. These tariffs, which align with the timeline of reciprocal and "Liberation Day" trade actions, were estimated to create a net headwind of approximately $20M to FY2025 adjusted net income as of the company's 1Q2025 guidance update in May 2025. By 2Q2025, management noted the impact was "slightly higher" than the initial $20M estimate but maintained that the company could absorb these costs through internal efficiencies and mitigation strategies.
The company's exposure is concentrated in the import of active pharmaceutical ingredients (APIs) from China for certain livestock products, as well as imported diagnostics equipment and veterinary accessories. Zoetis is uniquely positioned to weather these trade tensions due to its significant U.S. manufacturing presence. Approximately 60% of its products are manufactured in the U.S., making the company a net exporter. Consequently, management has identified retaliatory tariffs in international markets—particularly Europe, which is a major export destination—as a more significant potential risk than direct U.S. import duties on finished companion animal goods.
Mitigation strategies employed by Zoetis include tactical inventory shifts to delay cost impacts, leveraging its diversified global manufacturing network to dual-source materials, and strategic pricing adjustments. For FY2026, the company's guidance assumes the currently enacted tariffs are embedded in its financial baseline, though it does not account for the impact of potential future tariffs or further retaliatory actions. Management continues to monitor the fluid geopolitical environment, relying on its innovation-led model and geographic diversity to maintain its long-term growth trajectory despite these incremental costs.
Data
Tariff Impact on FY2025 Guidance
The table below summarizes the net tariff headwind and its inclusion in the company's financial guidance during 2025.
| Metric | Impact Estimate (Net) | Guidance Status |
|---|---|---|
| FY2025 Adjusted Net Income Headwind | ($20.0M)+ | Embedded in guidance since 1Q25 |
| Primary Exposure Categories | China-sourced APIs, Diagnostics | Livestock & Companion Animal segments |
| Manufacturing Footprint (U.S.) | 60.0% | Net Exporter status provides offset |
Source: Transcript 1Q-2025, Transcript 2Q-2025
Financial Impact
- Cost Impact (Historic): $20M
- Cost Impact (Forward-Looking): $20M
Sources
In terms of tariffs, net of mitigations, we're calling about $20mn of headwind that we're putting here.... Primarily from imports related to APIs for a few of our livestock products coming from China, and then some impact from a few of our diagnostics products.
The impact of currently enacted and assumptions on announced tariffs on our business is slightly higher than our estimate as of our May guidance update. However, we feel we can absorb the incremental impact for the year.
We export more out of the U.S. than we import into the U.S. Particularly when you think about companion animal, the vast majority of our sales are actually produced in the U.S. ... our exposure is really likely more from retaliatory tariffs from other jurisdictions.